Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 20/20 | 0.79 |
| ▸ | KIT | P10721 | 1/20 | 0.64 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.64 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.64 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.64 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.64 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.64 |
| ▸ | FLT3 | P36888 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13330484 | 0.92 | PDGFRB (0.83) | PDGFRBKITFGFR1PDGFRAFGFR2 | |
| SCHEMBL3318554 | 0.90 | PDGFRB (0.96) | PDGFRBKITFLT3 | |
| SCHEMBL4453685 | 0.89 | PDGFRB (0.79) | PDGFRBKITFGFR1PDGFRAFGFR2 | |
| SCHEMBL13330492 | 0.89 | PDGFRB (0.85) | PDGFRBKITFGFR1PDGFRAFGFR2 | |
| SCHEMBL13330494 | 0.87 | PDGFRB (1.00) | PDGFRBKITFGFR1PDGFRAFGFR2 | |
| SCHEMBL6336471 | 0.86 | PDGFRB (0.59) | PDGFRBKITFGFR1PDGFRAFGFR2 | |
| SCHEMBL13330491 | 0.83 | PDGFRB (0.84) | PDGFRBKITFGFR1PDGFRAFGFR2 | |
| SCHEMBL13360896 | 0.81 | PDGFRB (0.52) | PDGFRBKITFGFR1PDGFRAFGFR2 | |
| SCHEMBL3893578 | 0.80 | PDGFRB (0.84) | PDGFRBKITPDGFRAFLT3 | |
| SCHEMBL13330489 | 0.80 | PDGFRB (0.91) | PDGFRBKITFGFR1PDGFRAFGFR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1964839-A2 | Quinazoline derivatives as kinase inhibitors | Millennium Pharmaceuticals, Inc. (US) | 2008-09-03 | — | — | EP | claimed |
| US-20150133439-A1 | QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2015-05-14 | — | — | US | disclosed |
| US-20130274252-A1 | QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2013-10-17 | — | — | US | disclosed |
| US-8324205-B2 | Quinazoline derivatives as kinase inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-20100113468-A1 | QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-05-06 | — | — | US | disclosed |
| US-7560461-B2 | Quinazoline derivatives as kinase inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-07-14 | — | — | US | disclosed |
| US-7560461-B2 | Quinazoline derivatives as kinase inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-07-14 | — | — | US | disclosed |
| US-20090136450-A1 | THERAPY FOR NEUROLOGICAL DISEASES | ARES TRADING S.A. (CH) | 2009-05-28 | — | — | US | disclosed |
| EP-1964839-A2 | Quinazoline derivatives as kinase inhibitors | Millennium Pharmaceuticals, Inc. (US) | 2008-09-03 | — | — | EP | disclosed |
| EP-1919481-A2 | THERAPY FOR NEUROLOGICAL DISEASES | Ares Trading S.A. (CH) | 2008-05-14 | — | — | EP | disclosed |
| WO-2007014943-A2 | THERAPY FOR NEUROLOGICAL DISEASES | ARES TRADING S.A. (CH) | 2007-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150133439-A1 | QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | WNK2, WNK1, WNK3 | PDGFRB 10/4885KIT 495/4885FGFR1 281/4885 |
| US-20130274252-A1 | QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | WNK2, WNK1, WNK3 | PDGFRB 10/4885KIT 495/4885FGFR1 281/4885 |
| US-20100113468-A1 | QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | WNK2, WNK1, WNK3 | PDGFRB 10/4885KIT 495/4885FGFR1 281/4885 |
| US-20090136450-A1 | THERAPY FOR NEUROLOGICAL DISEASES | KIT, NGF, PMP22 | PDGFRB 191/4885KIT 1/4885FGFR1 925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.